Assessing Behavioral Risk Response mushroom

Assessing Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies

⏱ 3 min read🗓 Reviewed Oct 31, 2026🔬 AI-researched · Reviewed by Nathan Peters · How we grade the evidence

Bottom line: A Phase 2 trial is assessing whether electromagnetic and psychedelic therapies may be associated with changes in brain activity and symptoms in individuals at risk for PTSD, depression, and suicidality.

A new trial is exploring whether brain stimulation and psychedelic compounds may help reduce symptoms of PTSD, depression, and suicidality—without changing the way the brain fundamentally works. This study is not just another experiment; it’s a detailed look at how different risk groups might respond to new treatments.

Assessing Behavioral Risk Response mushroom
Original art — ShroomWire

What’s being tested

The PRE-EMPT trial is investigating whether electromagnetic therapies and psychedelic treatments can reduce suicidal ideation and alter neural activity in people with PTSD, major depression, and suicidality. It is testing three interventions: transcranial magnetic stimulation (TMS), psilocybin (a psychedelic compound), and neurofeedback using real-time fMRI and EEG. The study aims to determine if these treatments can help reduce symptoms and change the brain’s activity in key networks associated with emotional regulation and cognitive control.

The design at a glance

This is a Phase 2 trial, meaning it is focused on assessing the safety and potential effectiveness of the interventions in a larger group of participants. The trial is currently not yet recruiting, which means the research team is still preparing to begin enrollment. The sponsor is the University of New Mexico, and the study involves 150 participants from three risk groups: low, intermediate, and high risk for self-harm. The trial will collect clinical data, brain imaging, and molecular markers to build a comprehensive understanding of how these interventions might impact mental health outcomes.

Why it matters

If successful, this trial could pave the way for new, non-invasive treatments for individuals with severe mental health conditions. By combining advanced imaging techniques with molecular data, the study aims to improve the accuracy of risk prediction models and identify which interventions are most likely to help different patient groups. This could lead to more personalized and effective treatments for PTSD, depression, and suicidality, which are often difficult to manage with current therapies.

What this does NOT mean yet

It is important to note that this trial is still in the planning phase and has not yet begun recruiting participants. As such, there are no results to report, and the findings of this study are not yet available. Registration on ClinicalTrials.gov does not imply that the intervention is effective or safe; it simply means that the trial is being planned and may eventually begin. Many trials do not proceed past the planning stage, and even those that do may not yield positive results. Therefore, while this trial is worth watching, it is not yet evidence of any benefit.

How to follow it

You can follow the progress of the PRE-EMPT trial by visiting its record on ClinicalTrials.gov at https://clinicaltrials.gov/study/NCT07745569. Once the trial begins recruiting and enrolling participants, updates on its progress and any results will be posted there.

Sources

https://clinicaltrials.gov/study/NCT07745569 | NCT07745569

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.

Frequently asked questions

Is the PRE-EMPT trial testing new treatments for PTSD, depression, and suicidality?
Yes, the PRE-EMPT trial is investigating whether electromagnetic therapies and psychedelic treatments, such as psilocybin, can reduce symptoms of PTSD, depression, and suicidality.
What interventions are being tested in the PRE-EMPT trial?
The trial is testing three interventions: transcranial magnetic stimulation (TMS), psilocybin, and neurofeedback using real-time fMRI and EEG.
Is the PRE-EMPT trial currently recruiting participants?
No, the trial is not yet recruiting participants. The research team is still preparing to begin enrollment.
What is the purpose of the PRE-EMPT trial?
The purpose of the trial is to assess the safety and potential effectiveness of the interventions in reducing symptoms and altering neural activity in people with PTSD, major depression, and suicidality.
What does the PRE-EMPT trial NOT mean yet?
The trial is still in the planning phase and has not yet begun recruiting participants. Therefore, there are no results to report, and the findings of this study are not yet available.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *